Phase 2 RCT in 252 cognitively unimpaired Colombians (169 PSEN1 E280A carriers randomised): 5-8 years of crenezumab vs placebo did not significantly slow decline on the API ADAD composite (difference 0.33; p=0.43) or FCSRT-CI.
RCTn = 252
Tariot et al. Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial